Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
2 passages
5α-reductase inhibitors (5-ARIs), including finasteride and dutasteride, are approved by the U.S. Food and Drug Administration for treating benign prostatic hyperplasia and androgenic alopecia. These medications inhibit the enzyme 5α-reductase, reducing the conversion of testosterone into dihydrotestosterone, a hormone implicated in prostate enlargement and hair loss. This educational activity discusses the indications, mechanism of action, potential adverse events, and contraindications associated with 5-ARIs. The activity also covers off-label uses, appropriate dosing recommendations, and monitoring strategies to mitigate drug interactions and ensure patient safety. A significant focus is placed on the influence of 5-ARIs on prostate-specific antigen levels and the requisite prostate cancer screening protocols before initiating therapy. Through this activity, healthcare professionals gain knowledge vital for optimizing treatment outcomes for patients with conditions like benign prostatic hyperplasia, prostatic bleeding, and alopecia. The goal is to equip healthcare providers with the necessary knowledge to manage these conditions while adhering to safety protocols effectively. Objectives: Identify appropriate indications for 5α-reductase inhibitors, such as finasteride and dutasteride, in managing benign prostatic hyperplasia and androgenic alopecia. Implement standardized protocols for monitoring prostate-specific antigen levels and conducting prostate cancer screening before prescribing 5α-reductase inhibitors. Apply appropriate dosing recommendations for finasteride and dutasteride based on the indications and patient characteristics. Implement strategies with healthcare team members to coordinate comprehensive care for patients receiving 5-ARIs by addressing urological and dermatological concerns. Access free multiple choice questions on this topic.
The 5α-reductase inhibitors (finasteride and dutasteride) are effective treatments for both BPH and androgenic alopecia. Given the longer duration of symptom relief, patient education by nurses, pharmacists, and physicians is crucial to ensure adherence. Patients should be thoroughly informed about potential adverse effects and screened for prostate cancer before starting these medications.